Affordable Access

Publisher Website

Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia

Authors
Journal
Atherosclerosis
0021-9150
Publisher
Elsevier
Publication Date
Volume
100
Issue
1
Identifiers
DOI: 10.1016/0021-9150(93)90068-6
Keywords
  • Lipoprotein(A)
  • Ldl-Apheresis
  • Familial Hypercholesterolemia
  • Pravastatin
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Lipoprotein(a) (Lp(a)) was eliminated by LDL-apheresis using a dextran sulfate cellulose column in 3 homozygous and 10 heterozygous familial hypercholesterolemic patients. Immediately after LDL-apheresis by the LA-15 system (continuous LDL apheresis), there were significant reductions in Lp(a) concentrations (28.6 ± 11.8 mg/dl (mean ± S.E.) to 9.6 ± 5.6 mg/dl ( P < 0.01)), and in LDL-cholesterol concentrations (156 ± 32 mg/dl to 48 ± 18 mg/dl ( P < 0.01)). Immediately following LDL-apheresis, Lp(a) and LDL-cholesterol were reduced by 67.4% ± 11.6% and 68.3% ± 11.8%, respectively. The removal of Lp(a) paralleled that of LDL-cholesterol. The reduced levels of Lp(a) nearly returned to baseline within 7 days. In 6 of the heterozygous FH patients the rates of recovery of LDL cholesterol and Lp(a) were calculated, according to Apstein's equation after discontinuing lipid altering drug treatment for 4 weeks. Mean constant k values of LDL cholesterol and Lp(a) were 0.354 (range: 0.136–0.752) and 0.427 (range 0.112–0.933), respectively. The average concentration during the 7 days following LDL-apheresis was calculated. Average reductions were 28% in LDL cholesterol and 18% in Lp(a). Pravastatin treatment, which continued for 4 weeks, significantly decreased LDL cholesterol ( P < 0.01); however, before LDL-apheresis pravastatin treatment significantly increased Lp(a) levels ( P < 0.05) in a small number ( n = 6) of the FH patients, who had been regularly treated with LDL-apheresis. These results suggest that LDL-apheresis using the dextran sulfate cellulose column is an effective treatment to reduce levels of serum Lp(a) and LDL proportionally. This therapy may be of value in the prevention and regression of coronary artery disease in FH patients.

There are no comments yet on this publication. Be the first to share your thoughts.